KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Gross Profit (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Gross Profit for 7 consecutive years, with $397.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 216.51% year-over-year to $397.0 million, compared with a TTM value of $855.8 million through Dec 2025, up 95.18%, and an annual FY2025 reading of $855.8 million, up 95.18% over the prior year.
  • Gross Profit was $397.0 million for Q4 2025 at Biocryst Pharmaceuticals, up from $157.2 million in the prior quarter.
  • Across five years, Gross Profit topped out at $397.0 million in Q4 2025 and bottomed at $91.5 million in Q1 2024.
  • Average Gross Profit over 3 years is $175.3 million, with a median of $141.0 million recorded in 2025.
  • The sharpest move saw Gross Profit crashed 55.8% in 2024, then surged 216.51% in 2025.
  • Year by year, Gross Profit stood at $283.8 million in 2023, then plummeted by 55.8% to $125.4 million in 2024, then soared by 216.51% to $397.0 million in 2025.
  • Business Quant data shows Gross Profit for BCRX at $397.0 million in Q4 2025, $157.2 million in Q3 2025, and $160.6 million in Q2 2025.